Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.52 |
| ▸ | NPC1 | O15118 | 4/20 | 0.52 |
| ▸ | GAA | P10253 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
| ▸ | CYP4Z1 | Q86W10 | 2/20 | 0.44 |
| ▸ | S100B | P04271 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1259691 | 1.00 | KMT2A (0.52) | KMT2ANPC1GAAMAPTRAB9A | |
| SCHEMBL12528504 | 1.00 | KMT2A (0.52) | KMT2ANPC1GAAMAPTRAB9A | |
| SCHEMBL28242676 | 0.85 | CYP4Z1 (0.48) | KMT2ANPC1GAAMAPTRAB9A | |
| SCHEMBL13282569 | 0.83 | CA1 (0.54) | KMT2ANPC1MAPTRAB9AMEN1 | |
| SCHEMBL8809970 | 0.83 | S100B (0.49) | NPC1GAAMAPTRAB9ANPSR1 | |
| SCHEMBL28518807 | 0.83 | S100B (0.49) | KMT2ANPC1GAAMAPTRAB9A | |
| SCHEMBL30170219 | 0.83 | S100B (0.49) | NPC1GAAMAPTRAB9ANPSR1 | |
| SCHEMBL28243545 | 0.82 | MAPT (0.47) | KMT2ANPC1GAAMAPTRAB9A | |
| SCHEMBL28242729 | 0.82 | NPC1 (0.58) | KMT2ANPC1GAAMAPTMEN1 | |
| SCHEMBL654319 | 0.82 | LMNA (0.50) | KMT2ANPC1GAAMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4168114-A1 | SMALL MOLECULE MODULATORS OF IL-17 | LEO Pharma A/S (DK) | 2023-04-26 | — | — | EP | disclosed |
| EP-1948638-B1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORP (US) | 2011-08-03 | — | — | EP | disclosed |
| US-7968734-B2 | Organocatalysts and methods of use in chemical synthesis | STC.UNM (US) | 2011-06-28 | — | — | US | disclosed |
| US-7879997-B2 | Tumor necrosis factor-alpha converting enzyme inhibitors such as (2S,3R)-4-oxo-3-[[4-[(2-phenylquinolin-4-yl)methoxy]phenyl]methyl]azetidine-2-carboxylic acid, useful for the treatment of diseases or conditions mediated by matrix Metalloproteinases and tumor necrosis factor-alpha | SCHERING CORPORATION (US) | 2011-02-01 | — | — | US | disclosed |
| EP-1817273-B1 | METHOD FOR PREPARING DIASTEREOISOMERS OF 4-HYDROXY ISOLEUCINE | CENTRE NAT RECH SCIENT (FR) | 2010-01-27 | — | — | EP | disclosed |
| US-7612239-B2 | Method for asymmetric alkynylation of alpha-imino esters | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2009-11-03 | — | — | US | disclosed |
| EP-1948638-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION (US) | 2008-07-30 | — | — | EP | disclosed |
| US-20070244328-A1 | Organocatalysts and Methods of Use in Chemical Synthesis | STC.UNM (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070191332-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2007-08-16 | — | — | US | disclosed |
| WO-2007021803-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION (US) | 2007-02-22 | — | — | WO | disclosed |
| JP-2000256287-A | 1,2-DIAMINODIOL COMPOUND, ITS INTERMEDIATE AND THEIR PRODUCTION | SUMITOMO CHEM CO LTD | 2000-09-19 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244328-A1 | Organocatalysts and Methods of Use in Chemical Synthesis | SCO2, CBR1, CBR3 | KMT2A 2300/4885NPC1 902/4885GAA 4167/4885 |
| US-20070191332-A1 | Compounds for the treatment of inflammatory disorders | TNF, MMP8, MPO | KMT2A 3627/4885NPC1 1164/4885GAA 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.